Paraneoplastic syndromes

Current Opinion in Neurology

Volumn 10, Issue 6, 1997, Pages 471-476

  Posner, Jerome B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; IMMUNOGLOBULIN;

ANTIGEN EXPRESSION; HUMAN; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; REVIEW;

EID: 0030777830     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199712000-00006     Document Type: Review

References (47)

1. Brouwer B, Biemond A: Parenchymal cerebellar disease and its significance [in French]. J Beige De Neurol Psychiatry 1938, 38:691-757.
2. Denny-Brown D: Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948, 11:73-87.
3. Graus F, Elkon KB, Cordon-Cardo C, Posner JB: Sensory neuronopathy and small-cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 1986, 80:45-52.
4. Smitt PAES, Manley GT, Posner JB: Immunization with the paraneo-plastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995, 45:1873-1878.
5. Mason WP, Graus F, Lang B, Honnorat J, Delattre J-Y, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom Davis J et al.: Small-cell lung cancer, paraneoplastic cerebellar regeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997, 120:1279-1300.
6. Nathanson L, Hall TC: Paraneoplastic syndromes. Semin Oncol 1997, 24:265-372. This paper provides comprehensive review of paraneoplastic syndromes, both neurologic and nonneurologic.
7. Dalmau JO, Posner JB: Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997, 24:318-328.
8. Vickers SM, Niederhuber JE: Hodgkin's disease associated with neurologic paraneoplastic syndrome. South Med J 1997, 90:839-844.
9. Bolla L, Palmer RM: Paraneoplastic cerebellar degeneration - case report and literature review. Arch Intern Med 1997, 157:1258-1262.
10. Voltz RD, Posner JB, Dalmau J, Graus F: Paraneoplastic encephalo-myelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumor. J Neurol Neurosurg Psychiatry 1997, 63:133-136.
11. Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre J-Y: Limbic encephalitis and small cell lung cancer clinical and immunological features. Brain 1997, 120:923-928.
12. Lang B, Newson-Davis J: Immunopathology of the Lambert-Eaton myasthenic syndrome. In Immunoneurology. Edited by Chofflon M, Steinman L. Heidelberg 1996.
13. Nunn K, Ouvrier H, Sprague T, Arbuckle S, Docker M: Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome? J Child Neurol 1997, 12:276-281.
14. Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB: Motor neuron syndromes in cancer patients. Ann Neurol 1997, 41:722-730.
15. Carter GT, Fritz RC: Pancreatic adenocarcinoma presenting as a monomyelic motor neuronopathy. Muscle Nerve 1997, 20:103-105.
16. Rowland LP: Paraneoplastic primary lateral sclerosis and amyotrophic lateral sclerosis [Editorial]. Ann Neurol 1997, 41:703-705.
17. Heckman JG, Lang CJG, Druschky A, Claus D, Bartels O, Neundorfer B: Chorea resulting from paraneoplastic encephalitis. Movement Disord 1997, 12:464-466.
18. Grisold W, Udo Z, Markus D: Should every unclear neuromuscular sympton be termed 'paraneoplastic'? [Letter]. Muscle Nerve 1997, 20:1204-1205.
19. Krakauer J, Balmaceda C, Gluck JT, Posner JB, Fetell MR, Dalmau J: Anti-Yo-associated paraneoplastic cerebellar degradation in a man with adenocarcinoma of unknown origin. Neurology 1996, 46:1486-1487.
20. Byrne T, Mason WP, Posner JB, Dalmau J: Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997, 62:276-278.
21. Odell W. Metabolic syndromes of cancer. Semin Oncol 1997, 24:299-317. A review of paraneoplastic endocrine disorders is provided.
22. Lang B, Vincent A: Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 1996, 8:865-871.
23. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newson-Davis J: Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997, 147:35-42. Definitive assay of P/Q antibodies and their diagnostic role are outlined.
24. Takamori M, Iwasa K, Komai K: Antibodies to synthetic peptides of the alpha-1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 1997, 48:1261-1265. Epitope of VGCC eliciting immune response.
25. Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Prior CW, Wray D: Lambert-Eaton myasthenic syndrome. I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol 1987, 22:193-199.
26. Dau P, Denys E: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982, 11:570-575.
27. Kim Y: Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986, 9:523-530.
28. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, del Muro J, Vadell C et al: Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997, 15:2866-2872 Anti-Hu antibodies suppress tumor growth in humans with small-cell lung cancer.
29. Trotter JL, Hendin BA, Osterland K: Cerebellar degradation with Hodgkin'sdisease. An immunological study. Arch Neurol 1976, 33:660-661.
30. Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, Vecht CJ, Arbizu T, Targa C, Moll JWB: Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997, 74:55-61. A description of the antibody specific for PCD caused by Hodgkin's disease is provided.
31. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF: Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996, 61:270-278. A recently characterized paraneoplatic antibody is discussed.
32. Connolly A, Pestronk A, Mehta S, Pranzatelli M, Noetzel M: Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997, 130:878-884.
33. Antunes N, Khakoo Y, Stram D, Seeger R, Matthay K, Dalmau J: Antineuronal antibodies in patients with neuroblastoma and paraneo-plastic opsoclonus-myoclonus. Ann Neurol 1997, 42:534-535.
34. Tanaka M, Tanaka K: HLA A24 in paraneoplastic cerebellar degradation with anti-Yo antibody. Neurology 1996, 46:606-607.
35. Corradi JP, Yang CW, Darnell JC, Dalmau J, Darnell RB: The HuD paraneoplastic protein shares immunogenic regions between PEM/PSN patients and several strains and species of experimental animals. J Neuroimmunol 1996, 71:199-206
36. Tora M, Graus F, De Bolos C, Real FX: Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in small-cell lung cancers and neuroblastomas. Neurology 1997, 48:735-741. This paper gives a possible reason why a normal protein may elicit an immune response.
37. Quach TT, Rong Y, Belin MF, Duchemin AM, Akaoka H, Ding S, Baudry M, Kolattunkudy, Honnorat J: Molecular cloning of a new unc-33-like cDNA from rat brain and its relation to paraneoplastic neurological syndromes. Mol Brain Res 1997, 46:329-332. A newly cloned paraneoplasic antigen is discussed.
38. Corradi JP, Darnell RB: Evidence for an interaction of the paraneo-plastic cerebellar degeneration antigen cdr with c-myc [Abstract]. Soc Neurosci Abstr 1995, 21:487.
39. Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J: Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996, 91:519-525.
40. Corradi JP, Yang CW, Darnell JC, Dalmau J, Darnell RB: A post-transcriptional regulatory mechanism restricts expression of the para-neoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997, 17:1406-1415. This paper describes how antigen remains restricted to Purkinje cells.
41. Myer V, Xinhao F, Steitz J: Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. EMBO J 1997, 16:2130-2139. Function of Hu antigen is discussed.
42. Buckanovich R, Posner JB, Darnell R: Nova, the paraneoplastic R: antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993, 11:657-672.
43. Buckanovich R, Darnell R: The neuronal RNA binding protein nova-1 recognizes specific RNA targets In vitro and In vivo. Mol Cell Biol 1997, 17:3194-3201.
44. Uchuga M, Graus F, Vega F, Rene R, Delattre J-Y: Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996, 60:388-392.
45. Graus F, Vega F, Delattre J-Y, Bonaventura I, Rene R, Arbaiza D, Tolosa E: Plasmapheresis and antineoplastic treatment in CNS paraneo-plastic syndromes with antineuronal autoantibodies. Neurology 1992, 42:536-540.
46. David Y, Warner E, Levitan M, Sutton DMS, Malkin MG, Dalmau JO: Autoimmune paraneoplastic cerebellar degradation in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin a case repot. Cancer 1996, 78:2153-2156.
47. Furneaux HM, Reich L, Posner JB: Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990, 40:1085-1091.